Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from June 22, 2023, to June 24, 2025, Sarepta Therapeutics made materially false and misleading statements regarding ELEVIDYS, a gene therapy for Duchenne muscular dystrophy. Specific allegations include: - Significant safety risks associated with ELEVIDYS were not disclosed [3]. - Trial protocols failed to identify severe side effects [3]. - Adverse events from ELEVIDYS treatment could lead to halting recruitment and dosing in trials, attracting regulatory scrutiny [3]. - The misleading statements resulted in a lack of reasonable basis for the company's positive outlook on the therapy [3]. Class Action Details - Shareholders who purchased shares of SRPT during the specified class period are encouraged to register for the class action. The deadline for seeking lead plaintiff status is August 25, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud. The firm aims to ensure companies engage in responsible business practices [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of 3D Systems Corporation regarding a class action lawsuit due to alleged misleading statements and omissions made by the company during a specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from August 13, 2024, to May 12, 2025 [3]. - Allegations include that 3D Systems understated the impact of weakened customer spending and overstated its resilience in challenging industry conditions [3]. - Additionally, the updated milestone criteria in the partnership with United Therapeutics Corporation are claimed to negatively impact the company's regenerative medicine program revenue [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of August 12, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case [4]. Law Firm's Commitment - The Gross Law Firm aims to protect the rights of investors affected by deceit and illegal business practices, seeking recovery for losses incurred due to misleading statements by companies [5].

Core Insights - The article does not provide specific insights or analysis regarding any companies or industries, focusing instead on disclaimers and disclosures related to the author's positions and affiliations [1][2] Group 1 - No stock, option, or similar derivative positions are held by the author in any mentioned companies, nor are there plans to initiate such positions in the next 72 hours [1] - The article expresses the author's personal opinions and is not influenced by compensation from any company [1] - The views expressed may not reflect those of Seeking Alpha as a whole, and the analysts are not licensed securities dealers or investment advisers [2]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to misleading statements and a significant reduction in quarterly dividends, which led to a sharp decline in stock price [1][3]. Summary by Sections Class Action Details - Shareholders who purchased Organon shares between October 31, 2024, and April 30, 2025, are encouraged to contact the firm for potential lead plaintiff appointment [1][4]. - The allegations include that the defendants made overly positive statements while concealing adverse facts about Organon's capital allocation priorities, particularly regarding debt reduction after the acquisition of Dermavant [3]. Financial Impact - Following the revelation of the debt reduction strategy, Organon's regular quarterly dividend was reduced by 70%, causing the stock price to drop from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a decline of over 27% in one day [3]. Next Steps for Shareholders - The deadline for shareholders to register for the class action is July 22, 2025, and there is no cost or obligation to participate [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Krispy Kreme, Inc. regarding a class action lawsuit due to allegations of misleading statements related to the company's partnership with McDonald's and its impact on sales performance [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Krispy Kreme's management provided overly positive statements while concealing material adverse facts about the demand for Krispy Kreme products at McDonald's locations [3]. - It is claimed that lower demand at McDonald's led to declining average weekly sales per store, and the partnership was not profitable, prompting Krispy Kreme to pause expansion into new locations [3]. Financial Performance - On February 25, 2025, Krispy Kreme reported a net revenue decline of $404 million, a decrease of 10.4%, and a drop in average sales per door per week due to changing customer mix [3]. - Following this announcement, the stock price fell from $9.13 per share on February 24, 2025, to $7.13 per share on February 25, 2025 [3]. - On May 8, 2025, the company reported first quarter 2025 net revenue of $375.2 million, a decline of 15.3% or $67.5 million, and announced a reassessment of its partnership with McDonald's [3]. - The stock price further declined from $4.33 per share on May 7, 2025, to $3.26 per share on May 8, 2025, representing a drop of about 25% in one day [3]. Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are encouraged to register for the class action by July 15, 2025, to potentially become lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Reddit, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose material information that negatively impacted the company's stock performance [1][3]. Group 1: Allegations - The complaint alleges that during the class period from October 29, 2024, to May 20, 2025, Reddit's management made materially false and misleading statements [3]. - Key allegations include that changes in Google Search's algorithm led to a significant drop in traffic to Reddit, as users were able to find answers directly on Google without visiting Reddit [3]. - It is claimed that the defendants were aware of the zero-click search phenomenon, which was adversely affecting Reddit's user engagement and advertising revenues [3]. Group 2: Class Action Details - Shareholders who purchased RDDT shares during the specified class period are encouraged to register for the class action, with a deadline set for August 18, 2025 [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4]. - There is no cost or obligation for shareholders to participate in this class action [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=156058&from=3 CLASS PERIOD: A ...

Core Points - The Gross Law Firm has issued a notice to shareholders of Iovance Biotherapeutics, Inc. regarding a class action lawsuit for shareholders who purchased shares during the specified class period [1] - The class period is defined as May 9, 2024, to May 8, 2025, with allegations that Iovance provided misleading statements about its growth potential while concealing material adverse facts [3] - Following the announcement of disappointing financial results and a revenue guidance reduction on July 25, 2024, Iovance's stock price fell dramatically by approximately 44.795% in one day, from $3.17 to $1.75 per share [3] Allegations and Financial Impact - The complaint alleges that Iovance was not equipped to generate demand for its treatments and failed to capitalize on existing demand through its treatment centers [3] - The company attributed its poor financial results and lowered guidance to several factors, including maintenance of its iCTC, lower-than-expected Proleukin sales, and the variable pace of treatment initiation by ATCs [3] - The significant drop in stock price indicates a severe market reaction to the company's financial disclosures and guidance adjustments [3] Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 14, 2025, to participate in potential recovery efforts [4] - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4] - There is no cost or obligation for shareholders to participate in the class action [4]

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study following a Serious Adverse Event [3][4]. Summary by Sections Allegations - The complaint alleges that Rocket Pharmaceuticals made overwhelmingly positive statements to investors while concealing material adverse facts about RP-A501's safety and clinical trial protocol, including the risk of Serious Adverse Events (SAEs) and participant deaths [3]. - The company amended the trial protocol to introduce a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [3]. - Following the announcement of the FDA's clinical hold on May 27, 2025, due to a patient's death, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [3]. Class Action Details - The class period for the lawsuit is from February 27, 2025, to May 26, 2025, with a deadline for shareholders to register as lead plaintiffs by August 11, 2025 [4]. - Shareholders who register will receive updates on the case's status through portfolio monitoring software [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Conagra Brands (CAG) came out with quarterly earnings of $0.56 per share, missing the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.61 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.08%. A quarter ago, it was expected that this company would post earnings of $0.52 per share when it actually produced earnings of $0.51, delivering a surprise of -1.92%.Over the last four quarters, the company ha ...